182 V. Marzo et al.
Natarajan V, Schmid PC, Reddy PV, Schmid HH (1984) Catabolism of N-acylethanolamine
phospholipids by dog brain preparations. J Neurochem 42:1613–1619
Nirodi CS, Crews BC, Kozak KR, Morrow JD, Marnett LJ (2004) The glyceryl ester of
prostaglandin E2 mobilizes calcium and activates signal transduction in RAW264.7
cells. Proc Natl Acad Sci USA 101:1840–1845
O’Sullivan SE, Kendall DA, Randall MD (2004) Characterisation of the vasorelaxant proper-
ties of the novel endocannabinoid N-arachidonoyl-dopamine (NADA). Br J Pharmacol
141:803–812
Offertaler L, Mo FM, Batkai S, Liu J, Begg M, Razdan RK, Martin BR, Bukoski RD, Kunos
G (2003) Selective ligands and cellular effectors of a G protein-coupled endothelial
cannabinoid receptor. Mol Pharmacol 63:699–705
Ohno-Shosaku T, Matsui M, Fukudome Y, Shosaku J, Tsubokawa H, Taketo MM, Manabe
T, Kano M (2003) Postsynaptic M1 and M3 receptors are responsible for the mus-
carinic enhancement of retrograde endocannabinoid signalling in the hippocampus.
Eur J Neurosci 18:109–116
Oka S, Tsuchie A, Tokumura A, Muramatsu M, Suhara Y, Takayama H, Waku, Sugiura T
(2003)Ether-linkedanalogueof2-arachidonoylglycerol(noladinether)wasnotdetected
in the brains of various mammalian species. J Neurochem 85:1374–1381
Okamoto Y, Morishita J, Tsuboi K, Tonai T, Ueda N (2004) Molecular characterization of a
phospholipase D generating anandamide and its congeners. J Biol Chem 279:5298–5305
Ortar G, Ligresti A, De Petrocellis L, Morera E, Di Marzo V (2003) Novel selective and
metabolically stable inhibitors of anandamide cellular uptake. Biochem Pharmacol
65:1473–1481
Panikashvili D, Simeonidou C, Ben-Shabat S, Hanus L, Breuer A, Mechoulam R, Shohami E
(2001) An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. Nature
413:527–531
Parmentier-Batteur S, Jin K, Mao XO, Xie L, Greenberg DA (2002) Increased severity of
stroke in CB1 cannabinoid receptor knock-out mice. J Neurosci 22:9771–9775
Patricelli MP, Cravatt BF (2000) Clarifying the catalytic roles of conserved residues in the
amidase signature family. J Biol Chem 275:19177–19184
Pertwee RG (1997) Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther
74:129–180
Pertwee RG (2004) Novel pharmacological targets for cannabinoids. Curr Neuropharmacol
2:9–29
Petersen G, Hansen HS (1999) N-acylphosphatidylethanolamine-hydrolysing phospholi-
pase D lacks the ability to transphosphatidylate. FEBS Lett 455:41–44
Pinto L, Izzo AA, Cascio MG, Bisogno T, Hospodar-Scott K, Brown DR, Mascolo N, Di Marzo
V, Capasso F (2002) Endocannabinoids as physiological regulators of colonic propulsion
in mice. Gastroenterology 123:227–234
Piomelli D, Beltramo M, Glasnapp S, Lin SY, Goutopoulos A, Xie XQ, Makriyannis A (1999)
Structural determinants for recognition and translocation by the anandamide trans-
porter. Proc Natl Acad Sci USA 96:5802–5807
Portella G, Laezza C, Laccetti P, De Petrocellis L, Di Marzo V, Bifulco M (2003) Inhibitory ef-
fects of cannabinoid CB1 receptor stimulation on tumor growth and metastatic spread-
ing: actions on signals involved in angiogenesis and metastasis. FASEB J 17:1771–
1773
Porter AC, Sauer JM, Knierman MD, Becker GW, Berna MJ, Bao J, Nomikos GG, Carter
P, Bymaster FP, Leese AB, Felder CC (2002) Characterization of a novel endocannabi-
noid, virodhamine, with antagonist activity at the CB1 receptor. J Pharmacol Exp Ther
301:1020–1024
Premkumar LS, Qi ZH, Van Buren J, Raisinghani M (2004) Enhancement of potency and ef-
ficacyofNADAbyPKC-mediatedphosphorylationofvanilloidreceptor.JNeurophysiol
91:1442–1449